A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients

Trial Profile

A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Cyclophosphamide (Primary) ; Metformin (Primary) ; Olaparib (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions
  • Acronyms ENDOLA
  • Most Recent Events

    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
    • 29 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top